
Biocon Biologics’ Yesafili to enter US market, following agreement with Regeneron
Biocon Biologics announced a major milestone in its US expansion plans, inking a settlement and licensing agreement with Regeneron, allowing it to commercialise its biosimilar eye drug, Yesafili, in the country.Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is a biosimilar to the widely used ophthalmology drug Eylea (aflibercept)), and is used to treat various…